Umbilical cord blood (UCB) transplantation is being used as an alternative source of hematopoietic stem cells for bone marrow reconstitution. Separation and processing of UCB samples in large numbers for storage in cord blood banks ideally needs to be partially automated. The aim of this study was to establish and standardize a method for unrelated cord blood banking as well as the biological characterization of the samples. Up to October 1999, a total of 938 UCB units (mean volume 84.6 ؎ 23.6 ml, nucleated cell (NC) count 0.90 ؎ 0.37 ؋ 10 9 , total CFU-GM 79 ؎ 72 ؋ 10 4 , CD34 + cell count 2.46 ؎ 2.72 ؋ 10 6 ) had been collected. Twentythree per cent of all UCB samples had a NC count below 0.4 ؋ 10 9 and were discarded. The initial bacterial contamination rate was reduced to less than 5% as a result of extensive training in collection procedures. Using a modification of a triple bag system and adding a solution of 6% hydroxyethyl starch, the UCB was separated by two centrifugation steps into three components: buffy coat, red cell and plasma fractions. The overall recoveries for NC, CFU-GM and CD34 + cells were 87.4 ؎ 8.5%, 88.8 ؎ 6.6% and 90.3 ؎ 12.4%, respectively, in a mean final volume of 27 ؎ 4.2 ml. Bone Marrow Transplantation (2000) 26, 1263-1270.
Umbilical cord blood (UCB) has been used successfully since 1988 as a source of hematopoietic stem cells for transplantation involving sibling donors 1, 2 and, more recently, unrelated recipients. 3 UCB transplantation has been associated with a reduced risk of developing severe graft-versus-host disease (GVHD), even when cells from partially major histocompatibility complex mismatched donors are used. 4 UCB offers other advantages over bone marrow (BM): it is obtained without risk to either mother or infant as it is a waste product; the frequency of transmitting infections like cytomegalovirus is lower; and it can be stored fully tested and HLA typed, available for immediate use.
In the unrelated cord blood transplant setting, despite the higher HLA permissiveness, a large number of stored units are required and, consequently, the development of cord blood banks is necessary. The New York Blood Center has been a pioneer in this field. In 1994 Kurtzberg et al 5 reported the first two unrelated cord blood transplants, and to date more than 700 related and unrelated cord blood transplants have been performed. Successful hematopoietic and immunological engraftment can occur when UCB is the source of stem cells, even in cases of HLA antigen disparity between donor and recipient. 6, 7 As a result of these transplants more cord blood banks are being set up in Europe (London, Milan, Düsseldorf etc) as part of the European Cord Blood Bank Project (Eurocord), with more than 40 000 units currently stored all over the world. [8] [9] [10] Separation and processing of UCB samples in large numbers for storage in cord blood banks ideally needs to be partially automated to allow large numbers of samples to be processed efficiently. A closed system reduces the risk of bacterial contamination after collection. The processing method must allow for the adequate recovery of nucleated cells and progenitors to enable engraftment. Early attempts at separating cord blood by density gradient techniques led to loss of mononuclear cells which suggests that cord blood should be stored unseparated. However, volume reduction is essential for cord blood banks to be economical and efficient. Several different methods have been employed to reduce the volume prior to cryopreservation without loss of progenitor cells: density gradient separation, 11 sedimentation of red cells by gelatin, 12 rouleaux formation induced by hydroxyethyl starch (HES) and centrifugation, 13, 14 and differential centrifugation with expression of RCB and plasma. [15] [16] [17] In the present study, we describe the results obtained in our Cord Blood Bank using a modification of a triple bag system in which the UCB is separated by two centrifugation steps into three components: buffy coat, red cell and plasma fractions. This processing method allows for the maintenance of sterility, volume reduction and separation of red blood cells without a significant loss of stem cells.
Materials and methods

UCB collection bags
A triple bag collection system (PGR7357B; Baxter, Deerfield, IL, USA) with a 450 ml bag containing citrate-phosphate-dextrose-adenin (CPD-A) anticoagulant was used to collect the UCB. The bags were modified from the standard for our use by reducing the 63 ml of CPD-A to 20 ml by transferring the excess to the SAG manitol satellite bag, which was then sealed and removed, keeping the system closed.
Informed consent
The collection of cord blood was performed in the Departments of Obstetrics and Gynecology at the Complejo Hospitalario Universitario in Santiago de Compostela, the Hospital Xeral-Cíes in Vigo and the Hospital Arquitecto Marcide in Ferrol, by experienced midwives trained in cord blood collection, 5 days a week, covering a period of 24 h a day. Written informed consent was obtained from the mother for UCB collection, which could not be reserved for family use, for hepatitis and HIV testing at the time of delivery and for a maternal retest 6 months later (this sample is obtained using the infrastructure for the Blood Donation of the Galician Transfusion Center). Exclusion criteria were congenital malformations and known hereditary or blood-transmissible diseases affecting the fetus or the mother. At the time of delivery, the midwives also collected information on the type of delivery, sex, weight and condition of the infant. In Spain, 3 months after delivery the baby has to undergo a pediatric check report that is requested to be sent to the Bank.
UCB collection
The umbilical cord was doubly clamped and transected 10-30 s after the delivery of newborns of 32 or more weeks of gestation. After removal of the newborn from the operative field, the free end of the cord was wiped with betadine to ensure sterility of the collections. While the placenta was still in utero, the umbilical vein was punctured and the cord blood was collected by gravity in the collection bag. During cesarean sections or multiple births, after the birth of the baby, UCB was then collected from the removed placenta outside the operating theater. Efforts were made to obtain maximal volumes from each collection. The delivery of the newborn was not influenced in any way and, in particular, the clamping of the cord was not accelerated nor the delivery of the placenta delayed. After collection, 20 ml of venous blood were obtained from the mother and 3-5 cm of umbilical cord were taken to be frozen at −80°C. The UCB units were stored at 4°C, transported to the bank twice daily with the corresponding paperwork and processed within the following 24 h.
The volume of the cord blood collected was calculated from the weight of each collection minus the weight of the bag. Samples of 3 ml per unit were taken at this stage for HLA typing, a nucleated cell (NC) count, CD34
+ cell count and progenitor cell assays. Fungal, aerobic and anaerobic bacteriology cultures were performed on all donations.
Volume reduction
Before processing, the UCB unit was transferred to a 150 ml bag (4R2001; Baxter) and the HES containing solution (6% HES in 0.9 NaCl; Grifols, Barcelona, Spain) was added directly to the collection bag under sterile conditions in a proportion of 2:1 to wash the bag before mixing it with the cord blood. The UCB unit was first centrifuged at 40 g for 5 min, and the WBC-rich supernatant was expressed by the NPBI Compomat G4 system (Menarini, Valkenswaard, The Netherlands) into the original collection bag. A second centrifugation was done at 400 g for 10 min, and the plasma discarded into the satellite bag, leaving a mean volume of 27 ml (s.d. 4.2 ml, range 17-39 ml) of WBC and plasma in the bag. The complete process is performed in a closed system with the use of a sterile connecting device. The NC and CD34
+ cell estimations were repeated on the pelleted fraction, which, in addition to indicating the number of NC in the unit, allows for continuous quality monitoring of the process. After thoroughly mixing, the WBC contents of the processing bag were transferred to a freezing bag (Cryocyte 4R9951; Baxter).
Cryopreservation of cord blood
UCB processed units were cryopreserved using an automated microprocessor-controlled rate freezer (CryoMed, New Baltimore, MI, USA). Briefly, after chilling of the WBC, ice-cold freezing cryopreservative solution containing 60% DMSO (Braun, Boulogne, France) was added dropwise for 15 min. Samples for quality control of cryopreservation procedure were extracted before freezing and cryopreserved into cryotubes with the bag. The cells were immediately placed in aluminium cassettes in the chamber of the cell freezer, which used two thermocouple probes placed in a sample ampule containing freezing media. The cryopreservation protocol was as follows: 1°C/min cooling down to −60°C, followed by a drop to −120°C, 5°C/min. At the end of the freezing procedure the cells were stored in the liquid phase of a liquid nitrogen freezer.
Thawing of UCB samples after storage in liquid nitrogen
Thawing of the UCB unit for experimental work was performed as described by Katayama et al. 18 In summary, the UCB bag was thawed in a 37°C waterbath as rapidly as possible. Immediately, an aliquot of 3 ml was diluted slowly to 1/10 with a solution containing 10% human albumin (Grifols) in Iscove's modified Dulbecco's medium (Gibco BRL, Grand Island, NY, USA), followed by a centrifugation at 2500 r.p.m. for 10 min at 4°C. The supernatant was removed and the pelleted cells were resuspended in 2 ml of fresh solution. The parameters evaluated include: NC recovery, viability using Trypan blue, cytofluorometry for phenotype analysis and subpopulation viabilities, and clonogenic cell cultures.
Immunophenotyping
CD34
+ cell estimation was carried out on the whole blood prior to any processing and on the volume-reduced unit, after a method involving simultaneous staining with Becton Dickinson (BD) (San Jose, CA, USA) monoclonal anti-CD45 (anti-HLe-1), fluorescein isothiocyanate (FITC) and anti-CD34 (anti-HPCA-2) phycoerythrin (PE) conjugated antibodies. BD Simultest control ␥ 1 /␥ 2 was used as control. Flow cytometry was performed on a BD FACScan and Lysis II software was used for the analysis. CD45-positive events were gated into a region R1 on a fluorescence (FL)1 vs side scatter (SSC) dot plot to exclude nucleated red blood cells, platelets and debris. The CD45-positive events were analyzed for CD34 positivity by assessing events with low side scatter in a region R2 on a FL2 vs SSC dot plot. The absolute CD34
+ cell number is calculated on the basis of the WBC present after processing.
Progenitor cell assays
NC from whole blood were counted, viability assessed by Trypan blue exclusion, diluted to 1 ϫ 10 6 /ml in Iscove's modified Dulbecco's medium (Gibco) and plated in duplicate at 1 ϫ 10 5 /ml in Methocult GF H4434 (Stem Cell Technologies, Vancouver, Canada). Plates were incubated at 37°C in humidified 5% CO 2 . Granulocyte-macrophage colonies (CFU-GM) containing greater than 50 cells were scored by inverted microscope on day 10. The results are expressed as the total number of colonies in cord blood cells harvested and are based on the WBC count.
Bacteriology
Five ml from the residual red cell bag were transferred to aerobic, anaerobic (BacTAlert; Organon Teknika, Durham, NC, USA) and fungal (Bactec, BD) blood culture bottles, and they were then incubated at 37°C for 7 days. Positive cultures identified by measurement of CO 2 production were then plated on to agar plates. Any growth is subsequently identified using biochemical tests. The details of any bacterial contamination of a unit would be notified to the Transplant Center or Registry at first contact, when the unit is selected as a possible match for a patient. At this stage antibiotic sensitivity test will be performed on a frozen isolate.
Serologic and PCR testing of infectious diseases for banking
In Spain it is mandatory to analyze blood for hepatitis B surface antigen, anti-HIV 1-2, anti-HCV and TPHA for syphilis. An extended serology is performed, including anti-HTLV1-2, anti-CMV and anti-Toxoplasma. All units that test positive (excluding CMV and toxoplasmosis) are excluded from the bank. Three samples from mother and cord blood sera are stored at −80°C for further analysis (HIV and HCV by PCR).
DNA extraction
DNA was extracted from a 1.5 ml UCB sample using a standard salting out technique. 19 UCB mononuclear cells (MNC) were separated under sterile conditions using a Ficoll-Hypaque gradient.
HLA typing
Class I HLA typing (A and B loci) was done in fresh samples using a serologic method, while class II typing (HLA-DRB1/3/4/5) was determined from extracted DNA using low resolution PCR-SSP. Upon request, a confirmaBone Marrow Transplantation tory typing from a cryopreserved sample can be done. This typing includes high-resolution analysis of DRB loci.
Mother and cord blood cells are stored at −80°C for further analysis. DNA is frozen for dispatch to the transplant center if requested.
Searches
A preliminary report indicating the code, HLA typing, volume and cell content, as well as bacteriological and serological status of the UCB unit is issued to the requesting center. Upon request, high resolution class II and/or medium resolution HLA-Cw typing is carried out by SSP on the potentially selected unit.
The UCB donations were registered with Bone Marrow Donors Worldwide (BMDW) via the José Carreras Foundation.
Directed UCB donation service
Our bank offers the collection of UCB from siblings for children with leukemia or other hematological or immunological diseases, who may need a stem cell transplant. Referrals are made to a bank physician by the clinician treating the affected child. Special written consent is obtained from the mother and the obstetrician caring for her. A 24 h on-call service is provided. The mandatory microbiology markers are tested for prior to banking.
Detection of contaminating maternal cells in UCB
The AmpliType PM DNA test system (Perkin-Elmer, Applied Biosystems, Foster City, CA, USA), which combines information of 5 PM loci (LDLR, GYAP, HGBB, D7S8 and GC), was used as recommended by manufacturer. PCR was performed using designed primers in a GeneAmpPCR System 9600 instrument (Perkin-Elmer). Typing of the amplified products was performed by hybridization to DNA probe strips for the PM loci. Specifically hybridized amplified DNA is visualized upon enzymatic conversion of a soluble, colorless substrate to a blue-colored precipitate. Positive and negative controls were included in each batch of experiments.
Statistics
Results are expressed as mean Ϯ standard deviation (s.d.) and range (minimum-maximum). Correlations were analyzed by linear regression analysis.
Results
Cord blood collection
The Galician Cord Blood Bank began its activity in February 1998. Up to October 1999 a total of 938 cord blood units had been collected (60% of the donations). Ninetyeight per cent of the pregnant women informed about donation agreed to the collection, even though another 8% were excluded due to gynecological reasons. Twenty-three per cent of all UCB samples had a NC count below 0.4 ϫ 10 9 and were used for R&D; 9.7% did not meet the selection criteria and 29 units were discarded due to processing errors. 65% of all UCB samples had an mean volume of 80.1 ml (Figure 1 ), corresponding to a NC count of 0.82 ϫ 10
Bone Marrow Transplantation
9
. Even in the volume range of 40-60 ml, an average of 0.58 NC and 53.6 ϫ 10 4 CFU-GM can be obtained, still containing sufficient cell numbers for a pediatric transplant (Table 1 ).
An analysis of the volume collected vs the total numbers of NC obtained revealed that, on average, 10.51 ϫ 10 6 NC were obtained per milliliter of UCB collected (Figure 2 ), again indicating a normal distribution of NC/ml in UCB. This analysis indicated that some UCB collections had as many NC as some larger harvests and thus, we can set a cut-off volume of 40 ml of UCB. On average, a collection of more than 40 ml had a high probability of being clinically useful.
The number of NC obtained from a normal vaginal delivery, with the placenta in utero, was, on average, 13% higher 4-6.9 7-7.9 8-8.9 9-9.9 10-10.9 11-11.9 12-12.9 13-13.9 14-14. than samples obtained after a cesarean section (Table 2) . However, these mean counts are not the result of an increase in the volume of UCB. Furthermore, in a small number of difficult deliveries due to fetal distress, which in the end required no emergency medical attention after the birth, the average quantity of NC was also higher, although the volume obtained stayed at the same level.
As shown in Table 3 , it is possible to harvest significant numbers of UCB from multiple births. Although the absolute volume of UCB per infant is smaller than in singlet births, the collections are clinically useful. However, the percentage of discarded units due to a low volume or to Table 3 Comparison of cord blood volumes and nucleated cell counts obtained from multiple births, and both sexes the number of cells increased significatively, up to 48%, probably due to the collection being ex utero. Significant relationships between number of nucleated cells and volume (r = 0.75), number of CFU-GM (r = 0.61) and number of CD34 + cells (r = 0.65) were detected. No correlation was observed between the volume collected or the cell numbers and the sex (Table 3 ) nor the weight of the newborn (data not shown).
Processing and cryopreservation of UCB samples
Based on the literature and our previous results we have adapted the protocol with HES sedimentation for our banking activity. Up to April 1999, 388 units have been processed and cryopreserved using this method. Of these frozen units, data on 352 (91%) have been recorded in the registry of the BMDW and 25 (6.5%) have been discarded, mainly due to freezing problems (2.3%) or a positive screening serologic test (1.8%). Nine searches have been performed by transplant centers from Europe and the United States, and one unit has been reserved for transplantation. Eight units have been stored as part of the directed cord blood donation service.
The mean volume of fresh cord blood samples was 84.6 Ϯ 23.6 ml (range 45-172 ml). These results correlate with the mean total nucleated cell count of 0.90 Ϯ 0.37 ϫ 10 As shown in Table 4 (Table 5) . Also, RCB depletion of 80.8 Ϯ 
Recovery of UCB cells after cryopreservation
These measurements were made to compare the viability and clonogenic activity of the processed leukocytes tested after thawing and removal of DMSO. Twelve cord blood units were frozen for experimental work over an average period of 96 days ) and all samples were 99.9% viable at the time of cryopreservation. Cell viability was high in all cases inmediately after thawing (93.6 Ϯ 8.1%), decreasing to 78% after 1 h at 4°C, and no correlation existed between viability after thawing and final number of NC in the cryobags or duration of conservation (0.3-1.35 ϫ 10 9 cells/ml, data not shown). UCB samples were analyzed for the capacity to give rise to myeloid and granulocytic lineages after thawing and washing. The absolute CD34
+ cell number was also calculated. Table 6 shows the median cell recoveries.
Sterility of UCB samples
Since UCB transplant recipients are at particular risk of infections, extensive sterility tests were performed at the end of the processing. During the initial 6 months of the collection program, a microbial contamination rate up to 20% was observed, although in the second period, after extensive training of the midwives, this was reduced to below 5%. Typical skin flora species (eg Staphylococcus epidermidis and Corynebacterium sp) accounted for 82% of positive samples, perineal flora (eg Bacteroides sp. and Escherichia coli) for 13%, and infectious microorganisms (Streptococcus agalactiae) for the other 5%. These latter units were discarded.
Testing of serum for common infectious diseases
Five units were discarded following the results of the maternal virological screening (three anti-HIV1-2, one anti-HCV and three anti-HTLV1-2), even though no positive results were obtained in confirmatory tests. Fifty-eight and fifty-one per cent of the mothers tested positive for CMV and Toxoplasma, respectively. However, in no case was there any indication of an acute infection. Seventy per cent of the mothers were retested using the infrastructure of the Galician Transfusion Center for the Blood Donation.
Detection of contaminating maternal cells in UCB
To confirm the genetic integrity of the collected UCB samples 27 representative UCB units were recruited in this study and divided into three groups depending on the type of delivery (seven vaginal deliveries, six cesarean sections and 14 difficult births). DNA from mother and UCB samples was amplified in separate tubes to choose the most informative loci. Results are interpreted by observing the pattern and relative intensities of the blue dots on the wet strips to determine which alleles are present in each DNA Table 6 Effects of cryopreservation on cell viability and recovery of hemopoietic progenitors immediately after thawing (n = 12) sample, based on the assumption that the DNA present in the sample should reflect the corresponding cell content and that the alleles of the mother and the UCB should amplify accordingly. We detected maternal DNA in three cord blood samples, giving an incidence of 11% (one vaginal delivery and two difficult births).
Discussion
UCB is increasingly used as an alternative source of hematopoietic stem cells in related and unrelated allogeneic transplantation in children and adolescents. Data have shown that clinical outcome of cord blood transplantation depends on the number of nucleated cells transplanted, and most cord blood units do not contain enough stem cells for successful bone marrow reconstitution in adults. 6 Our aim was to assess the collection of UCB as well as volume reduction while maintaining sufficient progenitor cells to enable engraftment and reduce the risk of microbial contamination during processing. Kurtzberg et al 3 stated that the number of nucleated cells transfused per kilogram of body weight correlated with the rate of myeloid engraftment and that cell dose may be a more important indicator of engraftment than CD34
+ cell or CFU-GM values.
The optimal yield of mononuclear cells remains the most important aspect of UCB collection. The amount of fetal blood remaining in the placenta and the umbilical cord after clamping and dissection depends on several factors. The technique of UCB collection varies between different cord blood banks. 11, 13, 14, 20 For our study UCB was collected before and after placental delivery, but with no attempt at carrying out a randomized study. The collection from the placenta in utero is easy and does not disturb the natural course of birth or the postpartum period. Multiple punctures or placenta manipulation are other means of increasing the amount of UCB collected. The amount of NC obtained with the placenta still in utero was higher than for collections ex utero, even though the volume collected was similar using both techniques. Because of the immunocompromised state of UCB recipients, it is important to ensure the absence of possible pathogens in the graft. In relation to this, we were able to observe a decrease in bacterial contamination in the units collected after cesarean section, which is in keeping with the fact that 95% of the positive samples could be attributed to skin and vaginal flora. Improvement in protocols for the collection of UCB and the training of midwives have led to a fall in the rate of bacterial contamination, and, currently, we are testing another disinfection protocol that involves wiping the venopuncture site with 70% alcohol followed by an iodine bath.
Contamination of UCB with immunologically competent maternal T cells that could cause GVHD in the recipient is a theoretical concern since these may be a source of mature T lymphocytes incompletely matched with the recipient's histocompatibility antigens, and it is known that maternal cells can engraft in utero in infants born with severe combined immunodeficiency syndrome (SCID). 21 Although maternal cells can be detected in UCB at a frequency of less than 1 in 10 000 cells, no cases of GVHD secondary to engraftment of these cells has occurred to date, and no correlation between maternal cell content in the graft and incidence or severity of GVHD or graft rejection/ engraftment failure has been reported as yet. Some blood leakage from fetus/neonate to the mother occurs in up to 50% of births, usually during parturition, and, occasionally, clinically significant leakage occurs from mother to fetus. The magnitude of maternal contamination could be increased by UCB collection procedures, which try to collect optimal amounts of blood. 22 Through genomic HLA typing of the 352 validated units no cases of maternal DNA contamination were detected, but in 27 samples examined using PCR amplification of 5 loci PM, maternal DNA sequences were identified in three out of the 27 UCB samples. We set the amount of DNA in the sample to 2 ng of DNA, thus allowing us to detect maternal DNA at levels ranging from 0.1 to 1%. Increasing the amount of DNA to 5 ng also raises the sensitivity of this approach, although specificity is decreased. Our data show that maternal DNA can be detected in a significant proportion of UCB units obtained after uncomplicated pregnancies, more often after normal labor and delivery than after cesarean sections, even though more units have to be tested to give a significant correlation between different groups.
The mean volume collected, NC and CD34 + counts (84.6 Ϯ 23.6 ml, 0.90 Ϯ 0.37 ϫ 10 9 and 2.46 Ϯ 2.72 ϫ 10 6 ) using this system were similar to those reported worldwide. Moreover, the NC counts significantly correlated with the volume collected, number of CFU-GM and number of cells CD34
+ , in agreement with other studies. 16, 17 Due to the wide variation in and the lack of standardization for both CD34 + and clonogenic assays, comparison between laboratories is not currently valid, and thus, CD34
+ enumeration was performed on samples to indicate the presence of progenitor cells, and clonogenic assays are used for routine quality monitoring.
UCB cryopreservation as unmanipulated blood results in high costs for large-scale UCB banking. Depleting cord blood stem cells of RBC avoids exposure to incompatible red cell antigens, minimizes the infusion of free hemoglobin and limits the volume and the amount of DMSO needed for cryopreservation. Reducing the volume of UCB units should also help maintain their high cell viability, as the smaller volume allows them to be frozen more uniformly and thawed more rapidly. The capacity of volume-reduced UCB units to reconstitute hematopoiesis has been confirmed. 13 Several centers have used separation methods for UCB prior to cryopreservation, and good recoveries have been obtained following HES sedimentation, 14 3% gelatin sedimentation 12 or Ficoll density gradients. 11 Apart from the methods described by Rubinstein et al, 13 Sousa et al 15 and Armitage et al, 17 the manipulations are performed in open systems, incompatible with normal blood banking procedures. When the method does not involve a closed bag system of separation, the risk of microbial contamination is increased.
In comparison with other methods of sedimentation, HES 6% in NaCl does not require any laboratory preparation since it is commercially available and it can be used in a closed system, thus impeding possible microbial contamination during handling. It is frequently used in surgery for volume replacement 23 and is licensed in many countries for RCB removal from bone marrow to be used for transplantation. 24 Here, we describe a simple and effective system for UCB processing in a triple bag, which removes 80.8 Ϯ 5.8% of RCB and allows the storage of UCB units in small volumes, thus reducing the cost of large-scale UCB banking. The mean nucleated cell count of 0.78 Ϯ 0.31 ϫ 10 9 obtained after processing is within the range used for successful engraftment in both related and unrelated cord blood transplantation. Even larger volumes (Ͼ120 ml) of cord blood can be separated into much smaller units which could be cryopreserved into one bag unit for storage, thus increasing the efficiency of processing conditions in the case of a large number of samples under GMP without significant modification of normal blood banking procedures. Open-air procedures are not needed and all the processing can be done in bags connected via sterile dockers. With the addition of a volume of 60% DMSO instead of the traditional 20% DMSO, the units are frozen at a final average volume of 32 ml, which significantly reduced the storage requirement. Our data demonstrate that cryopreservation with concentrated DMSO solution maintained the clonogenic function of the thawed units. This smaller volume multiplies freezer capacity four-fold when storing UCB units in 50 ml cryobags and metal canisters. Another advantage of this method is that samples for ABO/RhD typing and microbiology screening can be removed from the red cell and plasma fractions, thereby increasing the volume of cryopreserved material for prospective testing. In conclusion, the method demonstrates that UCB units can be routinely processed in a closed system, that also achieves a significant reduction in storage needs and related costs, while maintaining quantity and quality of the progenitor cells.
